… the gastroenterologist a comprehensive summary of the … Cisapride was introduced worldwide
in the 1990s as a serotonin 5-… this withdrawal of tegaserod was a report by the Swiss drug …

… Results: Tegaserod was withdrawn in 2007 due to increased … and mucosal application of
serotonin activates local reflex … a concise summary of the abovementioned drugs used for …

… tegaserod, though effective, were ultimately withdrawn due to cardiovascular adverse events
due in part to receptor non-selectivity. Highly selective serotonergic … a plausible explanation …

… We did not measure lower gastrointestinal motility directly in … by treatment group using summary
statistics for baseline, each … Tegaserod was withdrawn because of its association with an …

… , was withdrawn owing to an increase in cases of ischemic colitis 99, 100 . Tegaserod, the
… earlier versions (any comments will already have been addressed in the published version). …

… Tegaserod appeared as safe as other drugs for IBS-C in … adverse event, resulting in study
drug discontinuation in 6.5% and 0.7… opioid receptors, gut serotonin receptors, secretagogue …

… new drug development for … withdrawal of cisapride, a 5-HT 4 agonist and 5-HT 3 antagonist,
because of its cardiovascular side effects, several serotonergic drugs including tegaserod …

… [Citation52], was withdrawn from the market after the report of … of tegaserod [Citation54]
led to a new approval of the drug … agents to treat gastrointestinal motility disorders [Citation66]. …

… for the treatment of functional motility disorders of the … on platelet aggregation induced by
ADP and serotonin plus … Following the voluntary withdrawal of tegaserod due to potential CV …

… analysis, we separately examined tegaserod, alosetron. The … led to the withdrawal of alosetron
and tegaserod, respectively, … interfering with serotonin signaling in such ischemic events. …